- Home
- DTIL vs SANG Comparison
DTIL vs SANG Comparison
Compare DTIL & SANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTIL | SANG |
|---|---|---|
| Founded | 2006 | 1984 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.3M | 163.0M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DTIL | SANG |
|---|---|---|
| Price | $7.01 | $4.31 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $45.00 | N/A |
| AVG Volume (30 Days) | ★ 232.9K | 4.0K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,070,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.53 | $3.71 |
| 52 Week High | $8.82 | $6.46 |
Technical Indicators
Market Signals| Indicator | DTIL | SANG |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 54.46 |
| Support Level | $4.56 | $3.71 |
| Resistance Level | $7.84 | $4.71 |
| Average True Range (ATR) | 0.53 | 0.15 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 59.50 | 86.15 |
Price Performance
Historical ComparisonAbout DTIL Precision BioSciences Inc.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).
About SANG Sangoma Technologies Corporation
Sangoma Technologies Corp is a provider of hardware and software components that enable or enhance Internet Protocol Communications Systems for both telecom and datacom applications. It is engaged in the development, manufacturing, distribution, and support of voice and data connectivity components for software-based communication applications. Its product includes data and telecom boards for media and signal processing, as well as gateway appliances and software. The Company sells into two geographic centers: USA and Other countries. Key revenue is generated from USA.